computer‐generated randomisation schedule (Glaxo Smith)
Structured Review
Lacerda 2019 " width="250" height="auto" />Computer‐Generated Randomisation Schedule, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computer-generated+randomisation+schedules/computer+generated+randomization+schedule/pmc08094590-85-16-20
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Tafenoquine for preventing relapse in people with Plasmodium vivax malaria"
Article Title: Tafenoquine for preventing relapse in people with Plasmodium vivax malaria
Journal: The Cochrane Database of Systematic Reviews
doi: 10.1002/14651858.CD010458.pub3
Lacerda 2019 " title="Lacerda 2019" property="contentUrl" width="100%" height="100%"/>
Figure Legend Snippet:
Techniques Used: Activity Assay, Infection, Sequencing, Selection
Llanos‐Cuentas 2014 " title="Llanos‐Cuentas 2014" property="contentUrl" width="100%" height="100%"/>
Figure Legend Snippet:
Techniques Used: Activity Assay, Infection, Sequencing, Selection, Generated
Related Articles
other:Article Title: Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study Article Snippet: Methods In this double-blind, randomised, dose-ranging phase 2b study, men and women (aged ≥16 years) with microscopically confi rmed P vivax monoinfection (parasite density >100 to <100 000 per μL blood) were enrolled from community health centres and hospitals across seven sites in Brazil, Peru, India, and Thailand.. Patients with glucose6-phosphate dehydrogenase enzyme activity of less than 70% were excluded.. Eligible patients received chloroquine (days 1−3) and were randomly assigned (1:1:1:1:1:1) by a computer-generated randomisation schedule to receive singledose tafenoquine 50 mg, 100 mg, 300 mg, or 600 mg, primaquine 15 mg for 14 days, or chloroquine alone. Article Title: Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial Article Snippet: Article Title: Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial Article Snippet: Patients were randomised centrally across all sites in accordance with a |

